Biomarkers in chronic graft-versus-host disease: quo vadis?
Biomarkers in chronic graft-versus-host disease: quo vadis?
复制标题
DOI：
10.1038/s41409-018-0092-x
复制
发表时间：
2018-07
影响因子：
4.8
通讯作者：
Schultz KR
中科院分区：
文献类型：
--
作者：
Wolff D;Greinix H;Lee SJ;Gooley T;Paczesny S;Pavletic S;Hakim F;Malard F;Jagasia M;Lawitschka A;Hansen JA;Pulanic D;Holler E;Dickinson A;Weissinger E;Edinger M;Sarantopoulos S;Schultz KR
生物标志物越来越多地用于诊断和治疗移植相关并发症，包括第一个生物标志物驱动的急性移植物抗宿主病（GvHD）介入试验。相比之下，慢性 GvHD (cGvHD) 生物标志物的开发则滞后，原因是其表现种类更广泛、与急性 GvHD 重叠、发病时间和最大严重程度的差异较大，以及前瞻性试验中缺乏足够的患者数量。 2017 年 3 月，北美和欧洲联盟在马赛举办了一次国际研讨会，旨在确定未来生物标志物开发策略，以指导 cGvHD 治疗。这次会议的结果是，优先考虑了两个领域：开发预测中度/重度 cGvHD 随后发生的预后生物标志物，同时开发用于生物标志物量化的合格临床级测定法。最有希望的预后血清生物标志物是 CXCL 9、ST2、基质金属蛋白酶-3、骨桥蛋白、CXCL 10、CXCL 11 和 CD163。尿液蛋白质组学和细胞亚群（CD4+ T 细胞亚群、co21low B 细胞）代表了 cGvHD 的其他潜在预后生物标志物。在任何潜在候选药物准备好进行验证和随后的临床应用之前，需要共同努力验证大量探索性试验的结果。
Biomarkers are increasingly used for diagnosis and treatment of transplant related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged due to a broader variety of manifestations, overlap with acute GvHD, a greater variability in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal of identifying strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers predicting the subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical grade assays for biomarker quantification. The most promising prognostic serum biomarkera are CXCL 9, ST2, matrix metalloproteinase-3, osteopontin, CXCL 10, CXCL 11 and CD163. Urine-proteomics and cellular subsets (CD4+ T cell subsets, co21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.
登录
查看更多内容
影响因子：
20.3
作者：
Kariminia, Amina;Holtan, Shernan G.;Schultz, Kirk R.
通讯作者：
Schultz, Kirk R.
影响因子：
4.3
作者：
Greinix, Hildegard T.;Pohlreich, David;Pickl, Winfried F.
通讯作者：
Pickl, Winfried F.
影响因子：
20.3
作者：
Abu Zaid, Mohammad;Wu, Juan;Choi, Sung Won
通讯作者：
Choi, Sung Won
DOI：
10.1158/1078-0432.ccr-15-1443
发表时间：
2016-01-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Arai S;Pidala J;Pusic I;Chai X;Jaglowski S;Khera N;Palmer J;Chen GL;Jagasia MH;Mayer SA;Wood WA;Green M;Hyun TS;Inamoto Y;Storer BE;Miklos DB;Shulman HM;Martin PJ;Sarantopoulos S;Lee SJ;Flowers ME
通讯作者：
Flowers ME
影响因子：
20.3
作者：
Alho, Ana C.;Kim, Haesook T.;Ritz, Jerome
通讯作者：
Ritz, Jerome